Covered recipient · General Payments record
MARIA V GARCIA PALLAS
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$13,834.70
141 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,818.00 | 4 |
| Food and Beverage | $3,216.70 | 135 |
| Consulting Fee | $1,800.00 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARIA V GARCIA PALLAS
NPI 1720019912 · CMS profile ID 383636
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
CAGUAS, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARIA V GARCIA PALLAS, NPI 1720019912, CMS profile ID 383636. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MARIA V GARCIA PALLAS, NPI 1720019912, CMS profile ID 383636. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MARIA V GARCIA PALLAS, NPI 1720019912, CMS profile ID 383636, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1720019912?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
141 matching records · $13,834.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–141 of 141.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation | $19.79 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150263261 | CMS |
| Amgen Inc. | $17.66 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111580704 | CMS |
| ABBVIE INC. | $14.03 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103774831 | CMS |
| Astellas Pharma US Inc | $18.95 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139324642 | CMS |
| GENZYME CORPORATION | $25.00 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139779070 | CMS |
| PBG PUERTO RICO LLC | $23.95 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131312785 | CMS |
| ARRAY BIOPHARMA INC | $15.59 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131419678 | CMS |
| PBG PUERTO RICO LLC | $22.74 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131295254 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $23.88 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135154736 | CMS |
| Janssen Pharmaceuticals, Inc | $24.53 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078167561 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7.67 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101260367 | CMS |
| Merck Sharp & Dohme LLC | $11.48 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141624798 | CMS |
| PBG PUERTO RICO LLC | $25.00 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131295250 | CMS |
| Merck Sharp & Dohme LLC | $16.36 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141845073 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.93 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101260355 | CMS |
| Exelixis Inc. | $14.50 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138561460 | CMS |
| SpringWorks Therapeutics, Inc. | $19.13 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1085804539 | CMS |
| Tempus AI, Inc | $20.60 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150164960 | CMS |
| Merck Sharp & Dohme LLC | $87.45 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141741745 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.95 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105482185 | CMS |
| Amgen Inc. | $22.74 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117257685 | CMS |
| Merck Sharp & Dohme LLC | $19.62 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141624900 | CMS |
| PBG PUERTO RICO LLC | $20.81 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131188634 | CMS |
| PFIZER INC. | $24.53 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131289073 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.45 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101260349 | CMS |
| PBG PUERTO RICO LLC | $22.95 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131421849 | CMS |
| Amgen Inc. | $23.59 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117257683 | CMS |
| Bayer Puerto Rico Inc. | $25.00 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086223728 | CMS |
| Verity Pharmaceuticals Inc. | $20.96 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1080605402 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.00 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105859162 | CMS |
| PBG PUERTO RICO LLC | $8.23 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131335024 | CMS |
| SOBI, INC | $19.74 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141436643 | CMS |
| Janssen Pharmaceuticals, Inc | $22.45 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078167717 | CMS |
| Janssen Pharmaceuticals, Inc | $25.00 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078167683 | CMS |
| Genentech USA, Inc. | $19.26 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133060663 | CMS |
| Tempus AI, Inc | $14.71 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150164958 | CMS |
| Genentech USA, Inc. | $19.98 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133060642 | CMS |
| Janssen Pharmaceuticals, Inc | $3.80 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078167665 | CMS |
| Exelixis Inc. | $18.76 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138561458 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.00 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104640931 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,106.00 | 01/09/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101260345 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,491,708.51 | 206 |
| PY2024 | Principal investigator | $226,882.82 | 19 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
206 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,129.00 | 12/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185540427 |
| Principal investigator 1 | ABBVIE INC. | $325.00 | 12/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202531182 |
| Principal investigator 1 | ABBVIE INC. | $10,290.80 | 12/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202531194 |
| Principal investigator 1 | PFIZER INC. | $369.00 | 12/15/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC Hosp Oncologico PR Medical Ctr | A GLOBAL PHASE 23 INTERVENTIONAL STUDY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228715541 |
| Principal investigator 1 | PFIZER INC. | $123.60 | 12/15/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC Hosp Oncologico PR Medical Ctr | A GLOBAL PHASE 23 INTERVENTIONAL STUDY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228716055 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,129.00 | 12/12/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 | No dispute reported | 06/30/2026 | 1185540425 |
| Principal investigator 1 | ABBVIE INC. | $4,229.66 | 12/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202527452 |
| Principal investigator 1 | ABBVIE INC. | $5,754.88 | 12/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202527454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,211.44 | 11/26/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223288777 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,755.00 | 11/13/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813119 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 11/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202523271 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 11/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202523273 |
| Principal investigator 1 | ABBVIE INC. | $10,398.12 | 11/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202523275 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $74,998.14 | 11/06/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials, Llc | A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1235994786 |
| Principal investigator 1 | ABBVIE INC. | $2,114.83 | 11/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202521843 |
| Principal investigator 1 | ABBVIE INC. | $10,961.66 | 11/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202521915 |
| Principal investigator 1 | ABBVIE INC. | $1,050.00 | 10/28/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202518793 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $220.61 | 10/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997270 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $69.96 | 10/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997272 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 10/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997274 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $73.00 | 10/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997276 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $19.60 | 10/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997278 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11.50 | 10/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997280 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 10/24/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518483 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 10/24/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518485 |
| Principal investigator 1 | ABBVIE INC. | $4,749.00 | 10/23/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202518341 |
| Principal investigator 1 | ABBVIE INC. | $1,050.00 | 10/23/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202518343 |
| Principal investigator 1 | ABBVIE INC. | $1,870.00 | 10/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517917 |
| Principal investigator 1 | ABBVIE INC. | $1,988.00 | 10/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517919 |
| Principal investigator 1 | ABBVIE INC. | $891.00 | 10/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517921 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,558.02 | 10/16/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223287045 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,571.00 | 10/15/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813115 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,126.00 | 10/15/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813117 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,286.00 | 10/10/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813107 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,286.00 | 10/10/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813109 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,800.00 | 10/10/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813111 |
| Principal investigator 1 | ABBVIE INC. | $10,290.80 | 10/09/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202515313 |
| Principal investigator 1 | ABBVIE INC. | $5,021.83 | 10/09/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202515537 |
| Principal investigator 1 | ABBVIE INC. | $5,341.95 | 10/08/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202513533 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,129.00 | 10/08/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185540421 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,447.55 | 10/06/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813113 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,432.43 | 10/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223286163 |
| Principal investigator 1 | ABBVIE INC. | $9,125.93 | 09/23/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202511894 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,194.00 | 09/10/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813105 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,413.10 | 09/09/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813103 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,883.75 | 09/08/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223285165 |
| Principal investigator 1 | ABBVIE INC. | $10,189.29 | 09/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202509318 |
| Principal investigator 1 | ABBVIE INC. | $11,157.41 | 09/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202509320 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,600.16 | 09/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223285121 |
| Principal investigator 1 | Celgene Corporation | $64,505.42 | 09/03/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials Llc | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | No dispute reported | 06/30/2026 | 1222306383 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,733.62 | 08/31/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials - Ciudadela | A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemoth | No dispute reported | 06/30/2026 | 1232923446 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,706.55 | 08/20/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813101 |
| Principal investigator 1 | ABBVIE INC. | $5,939.83 | 08/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202502825 |
| Principal investigator 1 | ABBVIE INC. | $2,805.30 | 08/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202502827 |
| Principal investigator 1 | ABBVIE INC. | $20,955.65 | 08/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202502867 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,286.00 | 08/01/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813097 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,286.00 | 08/01/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813099 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,127.60 | 08/01/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223283311 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $891.00 | 08/01/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223283313 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,468.80 | 08/01/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223283315 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $23,311.99 | 07/31/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223283301 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 07/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498842 |
| Principal investigator 1 | ABBVIE INC. | $1,870.00 | 07/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498844 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 07/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498856 |
| Principal investigator 1 | ABBVIE INC. | $1,988.00 | 07/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498858 |
| Principal investigator 1 | ABBVIE INC. | $891.00 | 07/18/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498878 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,172.00 | 07/17/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813095 |
| Principal investigator 1 | ABBVIE INC. | $10,398.12 | 07/16/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202498446 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 07/16/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202498452 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 07/16/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202498454 |
| Principal investigator 1 | ABBVIE INC. | $25,508.67 | 07/16/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202498460 |
| Principal investigator 1 | ABBVIE INC. | $10,728.20 | 07/15/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202498298 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,672.00 | 07/15/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813091 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,344.00 | 07/15/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813093 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,436.27 | 07/15/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282608 |
| Principal investigator 1 | ABBVIE INC. | $2,017.51 | 07/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202497740 |
| Principal investigator 1 | ABBVIE INC. | $1,366.20 | 07/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202497748 |
| Principal investigator 1 | ABBVIE INC. | $4,772.86 | 07/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202497750 |
| Principal investigator 1 | ABBVIE INC. | $3,806.33 | 07/10/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202497752 |
| Principal investigator 1 | ABBVIE INC. | $5,170.50 | 07/08/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202497442 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,413.10 | 07/08/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813089 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $837.68 | 07/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282258 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $607.50 | 07/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282260 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $607.50 | 07/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282262 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $202.50 | 07/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282264 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,618.50 | 07/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282212 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,571.20 | 07/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223282214 |
| Principal investigator 1 | ABBVIE INC. | $21,619.85 | 07/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202496453 |
| Principal investigator 1 | ABBVIE INC. | $5,587.48 | 07/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202496455 |
| Principal investigator 1 | ABBVIE INC. | $8,645.23 | 07/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202496461 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 06/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493669 |
| Principal investigator 1 | ABBVIE INC. | $573.75 | 06/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493671 |
| Principal investigator 1 | ABBVIE INC. | $789.75 | 06/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493673 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $576.98 | 06/24/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220997282 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $159.84 | 06/24/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220997284 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.00 | 06/24/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220997286 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $17.52 | 06/24/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220997288 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,706.55 | 06/09/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813087 |
| Principal investigator 1 | ABBVIE INC. | $9,841.09 | 06/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202489253 |
| Principal investigator 1 | ABBVIE INC. | $14,121.84 | 06/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202489255 |
| Principal investigator 1 | ABBVIE INC. | $8,467.20 | 06/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202489257 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $33,731.96 | 05/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280508 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $122.85 | 05/28/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280388 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,724.97 | 05/28/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280390 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $303.75 | 05/28/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280392 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,635.87 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280312 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,618.50 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280314 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $162.00 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280316 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,268.00 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280318 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,398.30 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280320 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,755.67 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280322 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $506.25 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280324 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $506.25 | 05/27/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280326 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $33,923.00 | 05/13/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813083 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,516.00 | 05/13/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813085 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,507.60 | 05/12/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813081 |
| Principal investigator 1 | ABBVIE INC. | $13,416.89 | 05/08/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202484255 |
| Principal investigator 1 | ABBVIE INC. | $5,106.81 | 05/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202482607 |
| Principal investigator 1 | ABBVIE INC. | $39,361.04 | 05/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202482615 |
| Principal investigator 1 | ABBVIE INC. | $11,576.25 | 05/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202484015 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $35,467.41 | 05/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278942 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,890.00 | 05/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278818 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,849.20 | 05/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278820 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,100.00 | 05/02/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278822 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $27,963.10 | 04/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278708 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,100.00 | 04/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278710 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 04/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278712 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 04/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278714 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 04/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278716 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $700.00 | 04/30/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278718 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $16.97 | 04/23/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997266 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11.66 | 04/23/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997268 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,227.50 | 04/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278186 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,586.00 | 04/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278188 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,618.50 | 04/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278190 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,618.50 | 04/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278192 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,403.43 | 04/17/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223278194 |
| Principal investigator 1 | Celgene Corporation | $37,070.00 | 04/09/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials Llc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1222306479 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27,013.00 | 04/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813077 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $925.00 | 04/07/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813079 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,794.75 | 04/04/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813067 |
| Principal investigator 1 | ABBVIE INC. | $16,783.42 | 04/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202470632 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,738.16 | 03/28/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223277119 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,980.65 | 03/26/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223277021 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,212.00 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223276989 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,980.65 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223276991 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,140.76 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223276993 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,620.00 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223276995 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $405.00 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223276997 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,047.30 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223277001 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,738.16 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223277003 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,140.76 | 03/25/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223277005 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $57,749.55 | 03/18/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813075 |
| Principal investigator 1 | ABBVIE INC. | $22,884.18 | 03/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202459332 |
| Principal investigator 1 | ABBVIE INC. | $23,983.00 | 03/07/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M24-536 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202459467 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,545.66 | 03/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223275719 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $356.37 | 02/25/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997254 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $209.88 | 02/25/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997256 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $179.82 | 02/25/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997258 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $109.50 | 02/25/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997260 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.40 | 02/25/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997262 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $24.00 | 02/25/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997264 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $350.00 | 02/13/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813073 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $25,065.00 | 02/11/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223275035 |
| Principal investigator 1 | ABBVIE INC. | $10,656.39 | 02/06/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202446880 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,263.00 | 02/06/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813071 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,993.00 | 02/05/2025 | Non-covered Recipient Entity Pan American Center for Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220813069 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,685.51 | 02/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274775 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,676.38 | 02/05/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274777 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $570.38 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274723 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,106.00 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274725 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,106.00 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274727 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,106.00 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274729 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,571.20 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274731 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,888.99 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274733 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,923.75 | 02/04/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223274735 |
| Principal investigator 1 | Genmab A/S | $22,000.00 | 02/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235932877 |
| Principal investigator 1 | Genmab A/S | $2,500.00 | 02/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235932880 |
| Principal investigator 1 | Genmab A/S | $1,538.00 | 02/03/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235932884 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442278 |
| Principal investigator 1 | ABBVIE INC. | $51.00 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442283 |
| Principal investigator 1 | ABBVIE INC. | $51.00 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442286 |
| Principal investigator 1 | ABBVIE INC. | $51.00 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442290 |
| Principal investigator 1 | ABBVIE INC. | $51.00 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442393 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,525.00 | 01/29/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers | No dispute reported | 06/30/2026 | 1185540423 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $169.70 | 01/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997246 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $93.28 | 01/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997248 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $59.94 | 01/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997250 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3.50 | 01/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials LLC | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220997252 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,516.18 | 01/27/2025 | Non-covered Recipient Entity Pan American Center For Oncology Trials - Ciudadela | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). | No dispute reported | 06/30/2026 | 1235994794 |
| Principal investigator 1 | ABBVIE INC. | $403.99 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440759 |
| Principal investigator 1 | ABBVIE INC. | $103.95 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440763 |
| Principal investigator 1 | ABBVIE INC. | $403.99 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440767 |
| Principal investigator 1 | ABBVIE INC. | $2,894.54 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440771 |
| Principal investigator 1 | ABBVIE INC. | $2,894.54 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440775 |
| Principal investigator 1 | ABBVIE INC. | $379.35 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440780 |
| Principal investigator 1 | ABBVIE INC. | $403.99 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440784 |
| Principal investigator 1 | ABBVIE INC. | $444.15 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440787 |
| Principal investigator 1 | ABBVIE INC. | $109.35 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440800 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440803 |
| Principal investigator 1 | ABBVIE INC. | $287.55 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440808 |
| Principal investigator 1 | ABBVIE INC. | $2,567.70 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440811 |
| Principal investigator 1 | ABBVIE INC. | $168.75 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440815 |
| Principal investigator 1 | ABBVIE INC. | $2,894.54 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440819 |
| Principal investigator 1 | ABBVIE INC. | $255.15 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440823 |
| Principal investigator 1 | ABBVIE INC. | $2,894.54 | 01/22/2025 | Non-covered Recipient Entity PAN AMERICAN CENTER FOR ONCOLOGY TRIALS LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202440827 |